MEDIUM confidence: 100% data completeness, but the composite (47) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $3.5B— | $4.0B+12.3% | $4.1B+3.9% | $4.0B-1.9% | $4.0B-0.9% |
| EPS (dil.) | $7.60— | $9.48+24.7% | $9.22-2.7% | $0.20-97.8% | $-2.91-1555.0% |
| Free Cash Flow | $532M— | $295M-44.6% | $365M+23.9% | $502M+37.3% | $518M+3.4% |
| Gross Margin | 37.7% | 36.8%-0.9pp | 36.4%-0.4pp | 32.9%-3.5pp | 30.5%-2.4pp |
| Operating Margin | 16.7% | 16.4%-0.3pp | 14.9%-1.4pp | 5.6%-9.3pp | 12.6%+7.0pp |
| Net Margin | 11.0% | 12.2%+1.2pp | 11.5%-0.7pp | 0.3%-11.2pp | -3.6%-3.8pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Fewer than 3 analysts refreshed a price target in the last month, so no revision can be computed. Prior quarter: $315 avg across 17 analysts.
Buy-rated share 78% → 83% over ~3 months (+6pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $2.74 | $3.02 | +10.2% |
| May 2026 | $1.96 | $2.06 | +5.1% |
| Feb 2026 | $2.33 | $2.39 | +2.6% |
| Nov 2025 | $2.32 | $2.43 | +4.7% |
| Aug 2025 | $2.50 | $3.12 | +24.8% |
| May 2025 | $2.06 | $2.34 | +13.6% |
| Feb 2025 | $2.50 | $2.66 | +6.4% |
| Nov 2024 | $2.42 | $2.59 | +7.0% |
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 5.1%/yr (revenue basis).
Base free cash flow $462M (avg FY2023–FY2025; latest year $518M) · equity value $17.2B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Net insider -$52.1M over 180 days (1 open-market buys, 21 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
The QScore of 47 for Charles River Laboratories indicates a neutral outlook, driven by strong momentum with a 12-month return of 97.9% and a bullish 50-day versus 200-day moving average. However, this is offset by low scores in value, with a high P/E and EV/EBITDA of 90.8, and growth, due to negative EPS growth of -1555.0%. The long-term score of 39 diverges from the short-term score of 55, suggesting a potential discrepancy between the company's current performance and its long-term prospects.